338 related articles for article (PubMed ID: 23942095)
1. Pharmacologic inhibition of Jak2-Stat5 signaling By Jak2 inhibitor AZD1480 potently suppresses growth of both primary and castrate-resistant prostate cancer.
Gu L; Liao Z; Hoang DT; Dagvadorj A; Gupta S; Blackmon S; Ellsworth E; Talati P; Leiby B; Zinda M; Lallas CD; Trabulsi EJ; McCue P; Gomella L; Huszar D; Nevalainen MT
Clin Cancer Res; 2013 Oct; 19(20):5658-74. PubMed ID: 23942095
[TBL] [Abstract][Full Text] [Related]
2. Structure-Based Screen Identifies a Potent Small Molecule Inhibitor of Stat5a/b with Therapeutic Potential for Prostate Cancer and Chronic Myeloid Leukemia.
Liao Z; Gu L; Vergalli J; Mariani SA; De Dominici M; Lokareddy RK; Dagvadorj A; Purushottamachar P; McCue PA; Trabulsi E; Lallas CD; Gupta S; Ellsworth E; Blackmon S; Ertel A; Fortina P; Leiby B; Xia G; Rui H; Hoang DT; Gomella LG; Cingolani G; Njar V; Pattabiraman N; Calabretta B; Nevalainen MT
Mol Cancer Ther; 2015 Aug; 14(8):1777-93. PubMed ID: 26026053
[TBL] [Abstract][Full Text] [Related]
3. STAT5A/B Blockade Sensitizes Prostate Cancer to Radiation through Inhibition of RAD51 and DNA Repair.
Maranto C; Udhane V; Hoang DT; Gu L; Alexeev V; Malas K; Cardenas K; Brody JR; Rodeck U; Bergom C; Iczkowski KA; Jacobsohn K; See W; Schmitt SM; Nevalainen MT
Clin Cancer Res; 2018 Apr; 24(8):1917-1931. PubMed ID: 29483142
[No Abstract] [Full Text] [Related]
4. Inhibition of STAT3 with orally active JAK inhibitor, AZD1480, decreases tumor growth in Neuroblastoma and Pediatric Sarcomas In vitro and In vivo.
Yan S; Li Z; Thiele CJ
Oncotarget; 2013 Mar; 4(3):433-45. PubMed ID: 23531921
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic potential of AZD1480 for the treatment of human glioblastoma.
McFarland BC; Ma JY; Langford CP; Gillespie GY; Yu H; Zheng Y; Nozell SE; Huszar D; Benveniste EN
Mol Cancer Ther; 2011 Dec; 10(12):2384-93. PubMed ID: 22027691
[TBL] [Abstract][Full Text] [Related]
6. Enzalutamide-Induced Feed-Forward Signaling Loop Promotes Therapy-Resistant Prostate Cancer Growth Providing an Exploitable Molecular Target for Jak2 Inhibitors.
Udhane V; Maranto C; Hoang DT; Gu L; Erickson A; Devi S; Talati PG; Banerjee A; Iczkowski KA; Jacobsohn K; See WA; Mirtti T; Kilari D; Nevalainen MT
Mol Cancer Ther; 2020 Jan; 19(1):231-246. PubMed ID: 31548294
[TBL] [Abstract][Full Text] [Related]
7. JAK kinase inhibition abrogates STAT3 activation and head and neck squamous cell carcinoma tumor growth.
Sen M; Pollock NI; Black J; DeGrave KA; Wheeler S; Freilino ML; Joyce S; Lui VW; Zeng Y; Chiosea SI; Grandis JR
Neoplasia; 2015 Mar; 17(3):256-64. PubMed ID: 25810010
[TBL] [Abstract][Full Text] [Related]
8. The novel JAK inhibitor AZD1480 blocks STAT3 and FGFR3 signaling, resulting in suppression of human myeloma cell growth and survival.
Scuto A; Krejci P; Popplewell L; Wu J; Wang Y; Kujawski M; Kowolik C; Xin H; Chen L; Wang Y; Kretzner L; Yu H; Wilcox WR; Yen Y; Forman S; Jove R
Leukemia; 2011 Mar; 25(3):538-50. PubMed ID: 21164517
[TBL] [Abstract][Full Text] [Related]
9. The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors.
Hedvat M; Huszar D; Herrmann A; Gozgit JM; Schroeder A; Sheehy A; Buettner R; Proia D; Kowolik CM; Xin H; Armstrong B; Bebernitz G; Weng S; Wang L; Ye M; McEachern K; Chen H; Morosini D; Bell K; Alimzhanov M; Ioannidis S; McCoon P; Cao ZA; Yu H; Jove R; Zinda M
Cancer Cell; 2009 Dec; 16(6):487-97. PubMed ID: 19962667
[TBL] [Abstract][Full Text] [Related]
10. Androgen receptor-dependent and -independent mechanisms driving prostate cancer progression: Opportunities for therapeutic targeting from multiple angles.
Hoang DT; Iczkowski KA; Kilari D; See W; Nevalainen MT
Oncotarget; 2017 Jan; 8(2):3724-3745. PubMed ID: 27741508
[TBL] [Abstract][Full Text] [Related]
11. Pharmacologic suppression of JAK1/2 by JAK1/2 inhibitor AZD1480 potently inhibits IL-6-induced experimental prostate cancer metastases formation.
Gu L; Talati P; Vogiatzi P; Romero-Weaver AL; Abdulghani J; Liao Z; Leiby B; Hoang DT; Mirtti T; Alanen K; Zinda M; Huszar D; Nevalainen MT
Mol Cancer Ther; 2014 May; 13(5):1246-58. PubMed ID: 24577942
[TBL] [Abstract][Full Text] [Related]
12. Transcription factor signal transducer and activator of transcription 5 promotes growth of human prostate cancer cells in vivo.
Dagvadorj A; Kirken RA; Leiby B; Karras J; Nevalainen MT
Clin Cancer Res; 2008 Mar; 14(5):1317-24. PubMed ID: 18316550
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of Stat5a/b Enhances Proteasomal Degradation of Androgen Receptor Liganded by Antiandrogens in Prostate Cancer.
Hoang DT; Gu L; Liao Z; Shen F; Talati PG; Koptyra M; Tan SH; Ellsworth E; Gupta S; Montie H; Dagvadorj A; Savolainen S; Leiby B; Mirtti T; Merry DE; Nevalainen MT
Mol Cancer Ther; 2015 Mar; 14(3):713-26. PubMed ID: 25552366
[TBL] [Abstract][Full Text] [Related]
14. Jak2-Stat5a/b Signaling Induces Epithelial-to-Mesenchymal Transition and Stem-Like Cell Properties in Prostate Cancer.
Talati PG; Gu L; Ellsworth EM; Girondo MA; Trerotola M; Hoang DT; Leiby B; Dagvadorj A; McCue PA; Lallas CD; Trabulsi EJ; Gomella L; Aplin AE; Languino L; Fatatis A; Rui H; Nevalainen MT
Am J Pathol; 2015 Sep; 185(9):2505-22. PubMed ID: 26362718
[TBL] [Abstract][Full Text] [Related]
15. Autocrine prolactin promotes prostate cancer cell growth via Janus kinase-2-signal transducer and activator of transcription-5a/b signaling pathway.
Dagvadorj A; Collins S; Jomain JB; Abdulghani J; Karras J; Zellweger T; Li H; Nurmi M; Alanen K; Mirtti T; Visakorpi T; Bubendorf L; Goffin V; Nevalainen MT
Endocrinology; 2007 Jul; 148(7):3089-101. PubMed ID: 17412813
[TBL] [Abstract][Full Text] [Related]
16. Activating mutation (V617F) in the tyrosine kinase JAK2 is absent in locally-confined or castration-resistant prostate cancer.
Gu L; Zhu XH; Visakorpi T; Alanen K; Mirtti T; Edmonston TB; Nevalainen MT
Anal Cell Pathol (Amst); 2010; 33(2):55-9. PubMed ID: 20966544
[TBL] [Abstract][Full Text] [Related]
17. Effect of AZD1480 in an epidermal growth factor receptor-driven lung cancer model.
Murakami T; Takigawa N; Ninomiya T; Ochi N; Yasugi M; Honda Y; Kubo T; Ichihara E; Hotta K; Tanimoto M; Kiura K
Lung Cancer; 2014 Jan; 83(1):30-6. PubMed ID: 24238495
[TBL] [Abstract][Full Text] [Related]
18. Hypoxic tumor kinase signaling mediated by STAT5A in development of castration-resistant prostate cancer.
Røe K; Bratland Å; Vlatkovic L; Ragnum HB; Saelen MG; Olsen DR; Marignol L; Ree AH
PLoS One; 2013; 8(5):e63723. PubMed ID: 23675504
[TBL] [Abstract][Full Text] [Related]
19. Transcription factor Stat5 knockdown enhances androgen receptor degradation and delays castration-resistant prostate cancer progression in vivo.
Thomas C; Zoubeidi A; Kuruma H; Fazli L; Lamoureux F; Beraldi E; Monia BP; MacLeod AR; Thüroff JW; Gleave ME
Mol Cancer Ther; 2011 Feb; 10(2):347-59. PubMed ID: 21216933
[TBL] [Abstract][Full Text] [Related]
20. Targeted Blockade of JAK/STAT3 Signaling Inhibits Ovarian Carcinoma Growth.
Gritsina G; Xiao F; O'Brien SW; Gabbasov R; Maglaty MA; Xu RH; Thapa RJ; Zhou Y; Nicolas E; Litwin S; Balachandran S; Sigal LJ; Huszar D; Connolly DC
Mol Cancer Ther; 2015 Apr; 14(4):1035-47. PubMed ID: 25646015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]